Cargando…

Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling

Acute myeloid leukemia (AML) is a high-mortality malignancy with poor outcomes. Azacitidine induces cell death and demonstrates treatment effectiveness against AML. Selinexor (KPT-330) exhibited significant benefits in combination with typical induction treatment for AML patients. Here, we explore t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Long, Huideng, Hou, Yue, Li, Jun, Song, Chunhua, Ge, Zheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094826/ https://www.ncbi.nlm.nih.gov/pubmed/37047788 http://dx.doi.org/10.3390/ijms24076816

Ejemplares similares

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
por: Nakayama, Robert, et al.
Publicado: (2016)

XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose
por: Crochiere, Marsha L., et al.
Publicado: (2017)

Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors
por: Binder, Adam F., et al.
Publicado: (2023)

XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies
por: Baek, Han Bit, et al.
Publicado: (2018)

XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB
por: Galinski, Basia, et al.
Publicado: (2021)

Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts
por: Rosen, Joshua C., et al.
Publicado: (2021)

Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia
por: Brinton, Lindsey T., et al.
Publicado: (2020)

XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53
por: Deng, Manman, et al.
Publicado: (2020)

Structure of the exportin Xpo4 in complex with RanGTP and the hypusine-containing translation factor eIF5A
por: Aksu, Metin, et al.
Publicado: (2016)

PB1810: SELINEXOR COMBINED WITH CX-4945 PROMOTES CELL DEATH BY TARGETING PIK3CD/AKT1/FOXO3 SIGNALING IN ACUTE MYELOID LEUKEMIA
por: Long, Huideng, et al.
Publicado: (2023)

Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia
por: Walker, Janek S., et al.
Publicado: (2021)

XPO1, therapeutic … and prognostic target in sarcomas
por: Bertucci, François, et al.
Publicado: (2016)

XPO1-Mediated EIF1AX Cytoplasmic Relocation Promotes Tumor Migration and Invasion in Endometrial Carcinoma
por: Ye, Yuhong, et al.
Publicado: (2022)

Venetoclax enhances DNA damage induced by XPO1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia
por: Yu, Hanxi, et al.
Publicado: (2022)

Protein biomarkers for response to XPO1 inhibition in haematologic malignancies
por: Totiger, Tulasigeri M., et al.
Publicado: (2023)

XPO1(E571K) Mutation Modifies Exportin 1 Localisation and Interactome in B-Cell Lymphoma
por: Miloudi, Hadjer, et al.
Publicado: (2020)

Cocktail hepatocarcinoma therapy by a super-assembled nano-pill targeting XPO1 and ATR synergistically
por: Gong, Liuyun, et al.
Publicado: (2023)

Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
por: Shang, Enyuan, et al.
Publicado: (2018)

Inhibition of XPO1 enhances cell death induced by ABT‐199 in acute myeloid leukaemia via Mcl‐1
por: Luedtke, Daniel A., et al.
Publicado: (2018)

XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma
por: Birnbaum, David Jérémie, et al.
Publicado: (2019)

XPO1-dependent nuclear export as a target for cancer therapy
por: Azizian, Nancy G., et al.
Publicado: (2020)

XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression
por: Fisher, Jack G., et al.
Publicado: (2023)

Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer
por: Sexton, Rachel, et al.
Publicado: (2019)

Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesis
por: Zhao, Lei, et al.
Publicado: (2021)

The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma
por: Sellin, Mark, et al.
Publicado: (2022)

Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors
por: Trkulja, Kyla L., et al.
Publicado: (2023)

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
por: Zhang, Weiguo, et al.
Publicado: (2018)

Proteomics identify nuclear export as a targetable pathway in neuroblastoma: Comment on “XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IκB”
por: Shah, Nilay
Publicado: (2021)

XPO1 regulates erythroid differentiation and is a new target for the treatment of β-thalassemia
por: Guillem, Flavia, et al.
Publicado: (2019)

A Radiosensitivity Gene Signature and XPO1 Predict Clinical Outcomes for Glioma Patients
por: Wu, Shan, et al.
Publicado: (2020)

Association of XPO1 Overexpression with NF-κB and Ki67 in Colorectal Cancer
por: Aladhraei, Mohammed, et al.
Publicado: (2019)

Inhibition of XPO-1 Mediated Nuclear Export through the Michael-Acceptor Character of Chalcones
por: Gargantilla, Marta, et al.
Publicado: (2021)

The nuclear export factor Xpo1p targets Mad1p to kinetochores in yeast
por: Scott, Robert J., et al.
Publicado: (2009)

Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition
por: Azmi, Asfar S., et al.
Publicado: (2015)

CRM1/XPO1 expression in pancreatic adenocarcinoma correlates with survivin expression and the proliferative activity
por: Saulino, David M., et al.
Publicado: (2018)

Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML
por: Pianigiani, Giulia, et al.
Publicado: (2022)

Regulation of XPO5 phosphorylation by PP2A in hepatocellular carcinoma
por: Li, Jiao, et al.
Publicado: (2022)

The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression
por: Deng, Manman, et al.
Publicado: (2023)

Verdinexor, a Selective Inhibitor of Nuclear Exportin 1, Inhibits the Proliferation and Migration of Esophageal Cancer via XPO1/c-Myc/FOSL1 Axis
por: Ou, Ling, et al.
Publicado: (2022)

Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignancies
por: Hing, Zachary A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9pa9fvgpq0no09s7mg012rov1r